Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. VivoSim Labs's pretax income for the
three
months ended in Mar. 2026 was €-4.99 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2026 was €-11.92 Mil.
VivoSim Labs's pretax margin was -14,245.71%.
During the past 13 years, VivoSim Labs's highest Pretax Margin was -756.05%. The lowest was -13457.80%. And the median was -908.37%.
VivoSim Labs (FRA:4OR) Pre-Tax Income Explanation
VivoSim Labs's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as
During the past 13 years, VivoSim Labs's highest Pretax Margin was -756.05%. The lowest was -13457.80%. And the median was -908.37%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VivoSim Labs Pre-Tax Income Related Terms
VivoSim Labs Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for VivoSim Labs's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4OR vs SLXN, CDT, CLDI: Pre-Tax Income Comparison
For the Biotechnology subindustry, VivoSim Labs's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs Pre-Tax Income vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-11.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VivoSim Labs (FRA:4OR) has a Pre-Tax Income of €-11.92 Mil as of Mar. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on VivoSim Labs and its competitors.
Is VivoSim Labs' Pre-Tax Income too high?
VivoSim Labs' current Pre-Tax Income is €-11.92 Mil. Overall, VivoSim Labs has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Pre-Tax Income compare to SLXN and CDT?
VivoSim Labs' Pre-Tax Income of €-11.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on VivoSim Labs and its competitors. VivoSim Labs's current Pre-Tax Income is €-11.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Pre-Tax Income of €-11.92 Mil. The stock's GF Value™ is €12.30, compared to a current price of €3.49 — trading 71.6% below its estimated fair value. The current Pre-Tax Income is €-11.92 Mil. VivoSim Labs' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Pre-Tax Income is €-11.92 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 71.6% below its estimated GF Value™ of €12.30.
Key valuation signals for FRA:4OR:
Pre-Tax Income: €-11.92 Mil
GF Value™: €12.30 vs. price of €3.49 (71.6% below fair value)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
33GF Score
Get the complete analysis for FRA:4OR
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
